Measure 397: Melanoma Reporting

Reporting Option: Claims, Registry

Quality Domain: Communication and Care Coordination

Description: Pathology reports for primary malignant cutaneous melanoma that include the pT category and a statement on thickness and ulceration and for pT1, mitotic rate

Instructions: This measure is to be reported each time a patient’s pathology report addresses specimens with a diagnosis of malignant cutaneous melanoma; however, only one QDC per date of service for a patient is required. This measure may be reported by eligible professionals who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.

Category II Codes:

G9428 Pathology report includes the pT Category and a statement on thickness and ulceration and for pT1, mitotic rate

Or

G9429 Documentation of medical reason(s) for not reporting pT Category and a statement on thickness and ulceration and for pT1, mitotic rate (e.g., negative skin biopsies in a patient with a history of melanoma or other documented medical reasons)

Or

G9430 Specimen site other than anatomic cutaneous location

Or

G9431 Pathology report does not include the pT Category and a statement on thickness and ulceration and for pT1, mitotic rate

CPT Codes: 88305

Diagnosis Codes:

Diagnosis for malignant cutaneous melanoma: C43.0, C43.20, C43.21, C43.22, C43.30, C43.31, C43.39, C43.4, C43.51, C43.52, C43.59, C43.60, C43.61, C43.62, C43.70, C43.71, C43.72, C43.8, C43.9

Clinical Recommendation Statements: In patients with localized melanoma (Stage I or II), Breslow tumor thickness, ulceration and mitotic rate are the three most important characteristics of the primary tumor predicting outcome.